Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Ioflupane

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    DATSCAN indication expanded to include use in patients with suspected DLB
    DATSCAN indication expanded to include use in patients with suspected DLB

    03 Nov 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221103005731/en

    BUSINESSWIRE
    03 Nov 2022
    Share Share
    Curium Announces FDA Approval of Generic Version of DaTscan in the U.S.
    Curium Announces FDA Approval of Generic Version of DaTscan in the U.S.

    05 Apr 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/04/05/2416189/0/en/Curium-Announces-FDA-Approval-of-a-Generic-Version-of-DaTscan-Ioflupane-I-123-Injection-in-the-U-S.html

    GLOBENEWSWIRE
    05 Apr 2022
    Share Share
    Curium's Generic Ioflupane Receives Approval in the U.S.
    Curium's Generic Ioflupane Receives Approval in the U.S.

    30 Mar 2022

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213792

    FDA
    30 Mar 2022
    Share Share
    DEA Proposes to Remove Cocaine Derivative [123I]Ioflupane from Schedule II of the CSA – Almost Five Years after Receipt of HHS’s Recommendation
    DEA Proposes to Remove Cocaine Derivative [123I]Ioflupane from Schedule II of the CSA – Almost Five Years after Receipt of HHS’s Recommendation

    04 Jun 2015

    // Karla L. Palmer FDA LAW BLOG

    http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2015/06/dea-proposes-to-remove-cocaine-derivative-123iioflupane-from-schedule-ii-of-the-csa-almost-five-year.html

    Karla L. Palmer FDA LAW BLOG
    04 Jun 2015
    Share Share